Pursuant to Article L-223-8 II of the Commercial Code and 223-16 of the AMF General Regulations.
SOPHIA ANTIPOLIS, France, June 08, 2022–(BUSINESS WIRE)–Regulatory news:
Median Technologies (Paris:ALMDT):
Total number of shares
Number of actual voting rights*
Theoretical number of voting rights*
Class E preferred shares are non-voting
(**) pursuant to Article 223-11 of the AMF General Regulation About Median Technologies:
Median Technologies provides innovative imaging solutions and services to advance healthcare for all. We harness the power of medical images using the most advanced artificial intelligence technologies, to increase the accuracy of the diagnosis and treatment of many cancers and other metabolic diseases in their early stages and provide information on new therapies for patients. . Our iCRO solutions for the analysis and management of medical images in oncology trials and iBiopsy®, our software powered by AI as a medical device, help biopharmaceutical companies and clinicians bring new treatments and diagnose patients earlier and more accurately. This is how we help create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the United States and another in Shanghai, Median has been awarded the “Innovative Company” label by BPI France and is listed on the Euronext Growth market (ISIN: FR0011049824 , mnemonic: ALMDT). Median is eligible for the SME Equity Savings Plan (PEA-PME), is listed on the Enternext® PEA-PME 150 index and has obtained the Euronext European Rising Tech label. For more information: www.mediantechnologies.com. See the source version on businesswire.com:
Corporate Marketing & Financial Communication Manager
+33 6 10 93 58 88
Press – ALIZE RP
+33 6 64 18 99 59
Investors – ACTIFIN
+33 6 21 10 49 24